Brain‐derived tau to measure treatment effect in Alzheimer's disease and frontotemporal dementia

Documenti analoghi

• Commentary on “It is time to share Alzheimer biomarker results in dementia with Lewy bodies”
  di: John T. O'Brien
  Pubblicazione: (2025)
• Examining the propensity and nature of criminal risk behaviours in frontotemporal dementia syndromes and Alzheimer's disease
  di: Fiona Kumfor, et al.
  Pubblicazione: (2024)
• Longitudinal changes in functional capacity in frontotemporal dementia and Alzheimer's disease
  di: David Foxe, et al.
  Pubblicazione: (2024)
• Association between BrainAGE and Alzheimer's disease biomarkers
  di: Yousaf Abughofah, et al.
  Pubblicazione: (2025)
• Preclinical dementia rating scores are associated with plasma phosphorylated tau‐217
  di: Qi Huang, et al.
  Pubblicazione: (2025)